Takeda Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3463000004
JPY
4,471.00
-24 (-0.53%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.42 M

Shareholding (Mar 2025)

FII

0.06%

Held by 2 FIIs

DII

99.94%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 5.12%

  • The company has been able to generate a Return on Capital Employed (avg) of 5.12% signifying low profitability per unit of total capital (equity and debt)
2

High Debt Company with a Debt to Equity ratio (avg) at times

3

Healthy long term growth as Net Sales has grown by an annual rate of 6.84% and Operating profit at 13.42%

 
4

The company declared very negative results in Mar'25 after flat results in Dec'24

5

With ROCE of 4.85%, it has a very attractive valuation with a 0.99 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 7,277,004 Million (Large Cap)

stock-summary
P/E

63.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.01%

stock-summary
Debt Equity

0.61

stock-summary
Return on Equity

3.08%

stock-summary
Price to Book

1.06

Revenue and Profits:
Net Sales:
1,106,685 Million
(Quarterly Results - Jun 2025)
Net Profit:
124,279 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.65%
0%
-1.65%
6 Months
2.43%
0%
2.43%
1 Year
8.68%
0%
8.68%
2 Years
10.18%
0%
10.18%
3 Years
9.29%
0%
9.29%
4 Years
45.12%
0%
45.12%
5 Years
15.32%
0%
15.32%

Takeda Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
6.84%
EBIT Growth (5y)
13.42%
EBIT to Interest (avg)
2.45
Debt to EBITDA (avg)
3.32
Net Debt to Equity (avg)
0.60
Sales to Capital Employed (avg)
0.37
Tax Ratio
37.38%
Dividend Payout Ratio
286.73%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
5.23%
ROE (avg)
4.36%
Valuation key factors
Factor
Value
P/E Ratio
63
Industry P/E
Price to Book Value
0.98
EV to EBIT
20.38
EV to EBITDA
8.42
EV to Capital Employed
0.99
EV to Sales
2.39
PEG Ratio
NA
Dividend Yield
0.01%
ROCE (Latest)
4.85%
ROE (Latest)
1.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.06% vs -7.93% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 220.54% vs -532.55% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,106,685.00",
          "val2": "1,053,399.00",
          "chgp": "5.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "372,232.00",
          "val2": "220,244.00",
          "chgp": "69.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "107,158.00",
          "val2": "50,324.00",
          "chgp": "112.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-74,102.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "124,279.00",
          "val2": "-103,098.00",
          "chgp": "220.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "172.20%",
          "val2": "28.90%",
          "chgp": "14.33%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 7.45% vs 5.87% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -25.00% vs -54.52% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,581,551.00",
          "val2": "4,263,762.00",
          "chgp": "7.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,388,939.00",
          "val2": "1,259,425.00",
          "chgp": "10.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "186,976.00",
          "val2": "153,631.00",
          "chgp": "21.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-220,252.00",
          "val2": "-217,776.00",
          "chgp": "-1.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "108,143.00",
          "val2": "144,197.00",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "137.00%",
          "val2": "124.60%",
          "chgp": "1.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,106,685.00
1,053,399.00
5.06%
Operating Profit (PBDIT) excl Other Income
372,232.00
220,244.00
69.01%
Interest
107,158.00
50,324.00
112.94%
Exceptional Items
0.00
-74,102.00
100.00%
Consolidate Net Profit
124,279.00
-103,098.00
220.54%
Operating Profit Margin (Excl OI)
172.20%
28.90%
14.33%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 5.06% vs -7.93% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 220.54% vs -532.55% in Mar 2025

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
4,581,551.00
4,263,762.00
7.45%
Operating Profit (PBDIT) excl Other Income
1,388,939.00
1,259,425.00
10.28%
Interest
186,976.00
153,631.00
21.70%
Exceptional Items
-220,252.00
-217,776.00
-1.14%
Consolidate Net Profit
108,143.00
144,197.00
-25.00%
Operating Profit Margin (Excl OI)
137.00%
124.60%
1.24%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 7.45% vs 5.87% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -25.00% vs -54.52% in Mar 2024

stock-summaryCompany CV
About Takeda Pharmaceutical Co., Ltd. stock-summary
stock-summary
Takeda Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available